Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS).

Saved in:
Bibliographic Details
Title: Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS).
Authors: Zschäbitz S; Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Im Neuenheimer Feld 460, 69120, Heidelberg, Germany. Stefanie.zschaebitz@med.uni-heidelberg.de., Bhatti I; Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Im Neuenheimer Feld 460, 69120, Heidelberg, Germany., Casuscelli J; Department of Urology, LMU University Hospital, LMU Munich, Munich, Germany., Pachmayr LO; School of Medicine and Health, Department of Urology, Technical University of Munich, TUM University Hospital, Munich, Germany., Büttner T; Department of Urology, University Hospital Bonn (UKB), Bonn, Germany., Elegeert T; Department of Urology and Pediatric Urology, Saarland University Medical Center, Saarland University, Homburg, Saar, Germany., Holzwarth N; Department of Urology and Pediatric Urology, University Hospital Würzburg, Würzburg, Germany., Rodler S; Department of Urology, University Hospital Schleswig Holstein, Kiel, Germany., Hennig M; Hospital Am Urban, Berlin, Germany., Rinderknecht E; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany., Dib M; Department of Urology, University Hospital Düsseldorf, Düsseldorf, Germany., Schlack K; Department of Urology, University Hospital Muenster, Muenster, Germany., Darr C; Department of Urology, German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany., Volk AL; Department of Urology, University Hospital Magdeburg, Magdeburg, Germany., Schmucker P; Department of Urology, University Hospital Freiburg, Freiburg, Germany., Zengerling F; Department of Urology Und Paediatric Urology, Hospital University of Ulm, Ulm, Germany., Paffenholz P; Department of Urology, Uro-Oncology, Robot Assisted and Reconstructive Urologic Surgery, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany., Heil J; Department of Hematology, Oncology, Palliative Care, Heilbronn Hospital, Heilbronn, Germany., Erne E; Department of Urology, Hospital University of Tübingen, Tübingen, Germany., Mandal S; Department of Urology, University Hospital Marburg and Philipps University Marburg, Marburg, Germany.; Department of Urology, Heidelberg University Hospital, Heidelberg, Germany., Wessels F; Department of Urology and Urological Surgery, University Medical Centre Mannheim, Mannheim, Germany., Busse TM; Department Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Medical University Hannover, Hannover, Germany., Seidl D; Department of Urology, Diakonie-Klinikum Stuttgart, Stuttgart, Germany., Foller S; Urology Department, Jena University Hospital, Jena, Germany.; Department of Urology, SRH Hospital, Gera, Germany., Höllein A; Department of Oncology, Red Cross Hospital, Munich, Germany.; Veramed Hospital, Brannenburg, Germany., Nestler T; Department of Urology, Bundeswehrkrankenhaus Koblenz, Koblenz, Germany., Gratzke C; Department of Urology, University Hospital Freiburg, Freiburg, Germany., Rhode L; Department of Urology, University Hospital Bonn (UKB), Bonn, Germany., Kohler J; Department of Urology, University Hospital Schleswig Holstein, Kiel, Germany., Niegisch G; Department of Urology, University Hospital Düsseldorf, Düsseldorf, Germany., Seitz AK; Department of Urology and Pediatric Urology, University Hospital Würzburg, Würzburg, Germany., Heinzelbecker J; Department of Urology and Pediatric Urology, Saarland University Medical Center, Saarland University, Homburg, Saar, Germany.; Department of Urology, University Hospital Marburg and Philipps-University Marburg, Marburg, Germany., Klümper N; Department of Urology, University Hospital Bonn (UKB), Bonn, Germany., Retz M; School of Medicine and Health, Department of Urology, Technical University of Munich, TUM University Hospital, Munich, Germany., Grünwald V; Institute for Urologic Oncology, West-German Cancer Center Essen, University Hospital Essen and German Cancer Consortium (DKTK), Essen, Germany., Aydogdu C; Department of Urology, LMU University Hospital, LMU Munich, Munich, Germany., Schnabel MJ; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany.
Source: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2026 Jul 12; Vol. 75 (7). Date of Electronic Publication: 2026 Jul 12.
Publication Type: Journal Article; Multicenter Study
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1432-0851
DOI:10.1007/s00262-026-04448-2